Abiopharma

🔍 Legorreta Pablo G. (Director)

Company: Royalty Pharma plc (RPRX)

Report Date: 2026-08-05

Detailed Transactions and Holdings:

• Acquired 65,216 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,307,820.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By Legorreta Children 2002 Trust | shares_owned_after: 1,040,410.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By GST-Exempt Legorreta 2012 Family Trust | shares_owned_after: 901,590.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By Legorreta 2023 SR Trust | shares_owned_after: 600,000.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By Legorreta Investments LLC | shares_owned_after: 460,139.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By Tata MC 35 Ltd. | shares_owned_after: 292,190.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By IRRA | shares_owned_after: 123,310.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By SEP/IRA | shares_owned_after: 118,500.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By GST-Exempt Legorreta 2020 Family Trust | shares_owned_after: 41,306.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By Son | shares_owned_after: 10,000.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By Daughter | shares_owned_after: 10,000.00
• Holds 0 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 6,930.00
• Sold 300,000 shares of LP interests in RPI US Partners 2019, LP (Derivative)
  Date: 2026-08-07 | Code: G | equity_swap_involved: 0 | shares_owned_after: 662,701.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Holds 37,074,880 shares of LP interests in RPI US Partners 2019, LP (Derivative)
  Date: 2026-08-05 | Code: H | shares_owned_after: 3,707,488.00 | Footnotes: F3, F3
• Holds 18,323,630 shares of LP interests in RPI US Partners 2019, LP (Derivative)
  Date: 2026-08-05 | Code: H | shares_owned_after: 1,832,363.00 | Footnotes: F3, F3
• Holds 1,470,140 shares of LP interests in RPI US Partners 2019, LP (Derivative)
  Date: 2026-08-05 | Code: H | shares_owned_after: 147,014.00 | Footnotes: F3, F3

Footnotes:

• F1: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
• F2: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.
• F3: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
• REMARKS: In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold 9,700,000 Class B Ordinary Shares exchangeable into 9,700,000 Class A Ordinary Shares and 13,356,742 Class E Ordinary Shares of Holdings exchangeable into 13,356,742 Class A Ordinary Shares. Class E Ordinary Shares of Holdings are subject to vesting conditions.